Intercept Pharmaceuticals, Inc. (ICPT) CEO Mark Pruzanski on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/05/19
Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/05/19
Intercept Announces New NASH and PBC Data to be Presented at The Liver Meeting® 2019GlobeNewsWire • 10/28/19
Analysts Estimate Intercept Pharmaceuticals (ICPT) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/23/19
Intercept Submits New Drug Application to the U.S. FDA for Obeticholic Acid in Patients with Fibrosis Due to NASHGlobeNewsWire • 09/27/19
Intercept Launches NASHTRUTH.com, an Online Educational Resource for People with Advanced Fibrosis Due to NASHGlobeNewsWire • 09/11/19
Intercept Pharmaceuticals, Inc. (ICPT) CEO Mark Pruzanski on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/07/19
Will Intercept Pharmaceuticals (ICPT) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/25/19